Russian results of the international epidemiological study of clinical aspects and resistance to antimicrobial medicines of cystitis uropathogens in females (ARESC): significance of empiric therapy


Citar

Texto integral

Resumo

A total of 656 female patients from Russia aged between 18 to 65 years with uncomplicated cystitis entered the international ARESC trial, of them 647 were eligible for final analysis. Positive cultural urine tests ( > 104 CFU/ml) were in 419 (64.7%) patients, 393 (93.8%) patients had monoinfection. The central laboratory of Genoa (to which the isolated samples were sent) has tested 416 uropathogens from 399 patients. The following pathogens were isolated: E.coli (72.6%), enterococcus (7.0%), Klebsiella pneumoniae (4.6%), Staphylococcus saprophyticus (3.6%), Proteus mirabilis (2.4%) and Staphylococcus aureus (1.7%). E.coli was most sensitive to phosphomycin (99.3%), mecillinam (97.3%), nitrofurantoin (94.7%), ciprofloxacin (87.4%). The lowest sensitivity was to ampicillin (42.1%) and cotrimoxasol (69.4%). As to the whole bacterial spectrum, the highest sensitivity was found to phosphomycin (96.5%), nitrofurantoin (85.6%) and citrofloxacin (82.8%), the less sensitivity - to ampicyllin (44.3%) and co-trimoxasol (70.1%). Phosphomycin, mecillinam (not registered in Russia) and nitrofurantoin showed activity in vitro and can be considered as drugs of choice for empiric therapy of cystitis. Because of high resistance of pathogens, co-trimoxasol (trimetoprim) and fluoroquinalones are not recommended as first-line treatment for uncomplicated cystitis in females.

Bibliografia

  1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity and economic costs. Am. J. Med. 2002; 113 (Suppl. 1A): 5S-13S.
  2. Kunin C. Detection, prevention and management of UTIs. 5-th ed. Philadelphia: Lea & Febiger; 1997.
  3. Krieger J. N., Ross S. O., Simonsen J. M. Urinary tract infections in healthy university men. J. Urol. (Baltimore) 1993; 149: 1046-1048.
  4. Stamm W. E. Urinary tract infections in young men. In: Bergan T., ed. Urinary tract infections. Basel: Karger; 1997. 46-47.
  5. Nicolle L. E. Urinary tract infections in diabetes. Curr. Opin. Infect. Dis. 2005; 18: 49-53.
  6. MacLean A. B. Urinary tract infection in pregnancy. Br. J. Urol. 1997; 80 (Suppl. 1): 10-13.
  7. Raz R., Gennesin Y., Wasser J. et al. Recurrent urinary tract infections in postmenopausal women. Clin. Infect. Dis. 2000; 30: 152-156.
  8. Grabe M., Bjerklund-Johansen T. E., Botto H. et al. Guidelines on urological infections.In: EAU. Guidelines edition 2010.
  9. Naber K. G., Schito G., Botto H. et al. Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for Empiric Therapy. Eur. Urol. 2008; 54: 1164-1178.
  10. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7-th ed. Wayne, PA: CLSI; 2006.
  11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 17-th informational supplement. Wayne, PA: CLSI; 2007.
  12. Stamm W. E., Counts G. W., Running K. R. et al. Diagnosis of coliform infection in acutely dysuric women. N. Engl. J. Med. 1982; 307: 463-468.
  13. Schito G. C., Gualco L., Naber K. G. et al. Do different susceptibility breakpoints affect the selection of antimicrobials to treat uncomplicated cystitis? J. Chemother. 2010.
  14. Schito G. C. Why fosfomycin trometanol as first line therapy for uncomplicated UTI? Int. J. Antimicrob. Agents 2003; 22 (Suppl. 20): S79-S83.
  15. Hooton T. M. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int. J. Antimicrob. Agents 2003; 22: S65-S72.
  16. Kahlmeter G. The ECO-SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens - interim report. J. Antimicrob. Chemother. 2000; 46 (Suppl. S1): 15-22.
  17. Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO SENS study. Int. J. Antimicrob. Agents 2003; S49-S52.
  18. Fadda G., Nicoletti G., Schito G. C., Tempera G. Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines. J. Chemother. 2005; 17: 251-257.
  19. Lecomte F., Allaert F. A. Single-dose treatment of cystitis with fosfomycin trometanol (Monuril): analysis of 15 comparative trials on 2,048 patients. G. It. Ostetr. Ginecol. 1997; 19: 399-404.
  20. Minassian M. A., Lewis D. A., Chattopadhyay D. et al. A comparison between single-dose fosfomycin trometanol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int. J. Antimicrob. Agents 1998; 10: 39-47.
  21. Stein G. E. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin. Ther. 1999; 21: 1824-1872.
  22. Nicolle L. E. Pivmecillinam in the treatment of urinary tract infections. J. Antimicrob. Chemother. 2000; 46 (Suppl. 1): 35-39.
  23. Nicolle L. E., Madsen K. S., Debeeck G. O. et al. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand. J. Infect. Dis. 2002; 34: 487-492.
  24. Goettsch W. G., Janknegt R., Herings R. M. Increased treatment failure after 3-days' courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the PHARMO database. Br. J. Clin. Pharmacol. 2004; 58: 184-189.
  25. Spencer R. C., Moseley D. J., Greensmith M. J. Nitrofurantoin modified release versus trimethoprim or cotrimoxazole in the treatment of uncomplicated urinary tract infection in general practice. J. Antimicrob. Chemother. 1994; 33 (Suppl. A): 121-129.
  26. Gupta K., Hooton T. M., Roberts P. L., Stamm W. E. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch. Intern. Med. 2007; 167: 2207-2212.
  27. Hooton T. M., Scholes D., Gupta K. et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. J. A. M. A. 2005; 293: 949-955.
  28. Naber K. G., Koch E. M. Cefuroxime axetil versus ofloxacin for short-term therapy of acute uncomplicated lower urinary tract infections in women. Infection 1993; 21: 34-39.
  29. Naber K. G. Survey on antibiotic usage in the treatment of urinary tract infections. J. Antimicrob. Chemother. 2000; 46 (Suppl. S1): 49-52.
  30. Warren J. W., Abrutyn E., Hebel J. R. et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin. Infect. Dis. 1999; 29: 745-758.
  31. Raz R., Chazan B., Kennes Y. et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with high prevalence of TMP-SMX resistant uropathogens. Clin. Infect. Dis. 2002; 34: 1165-1169.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2011